Methods for Stabilizing Atherosclerotic Plaques Using Lipoxins, Resolvins, and Analogs Thereof

1 . A method of treating or preventing an arterial disorder by increasing plaque stabilization in a subject in need thereof comprising administering a therapeutically effective amount of lipoxin A 4 (LXA 4 ), resolvin, or analog thereof to the subject to thereby treat or prevent the arterial disorder by increasing plaque stabilization.

2 . The method of claim 1 , wherein the arterial disorder is characterized by the presence of unstable/vulnerable atherosclerotic plaques.

3 . The method of claim 1 or 2 , wherein the lipoxin A 4 (LXA 4 ), resolvin, or analog thereof is formulated in a pharmaceutically acceptable carrier.

4 . The method of claim 3 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of mouth rinses, chewing gum, food additives, lozenges, tablet, chewable capsule, intraoral delivery devices and encapsulated in resporbable carrier nanoparticles of biologic or synthetic origin.

5 . The method of claim 1 , wherein the effective amount of the agent is an amount that increases plaque stabilization and/or reduces the number of unstable/vulnerable plaques.

6 . The method of claim 1 , further comprising administering at least one additional agent that treats the arterial disorder that would benefit from increased plaque stabilization.

7 . The method of claim 6 , wherein the additional agent is selected from the group consisting of anti-inflammatory agents.

8 . The method of claim 1 , wherein the LXA 4 analog is 9,12 benzo-LXA 4 .

9 . The method of claim 1 , wherein the resolvin is Resolvin E1.

10 . The method of claim 1 , wherein the administration is topical.

11 . A method of treating arterial disease in a subject in need thereof comprising:

a) performing surgery upon at least one arterial lesion of the subject; and

b) administering a therapeutically effective amount of lipoxin A 4 (LXA 4 ), resolvin, or analog thereof to the surgical wound at the time of surgery;

to thereby treat the arterial disease in the subject.

12 . The method of claim 11 , wherein the lipoxin A 4 (LXA 4 ), resolvin, or analog thereof is formulated in a pharmaceutically acceptable carrier.

13 . The method of claim 12 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of mouth rinses, chewing gum, food additives, lozenges, tablet, chewable capsule, intraoral delivery devices and encapsulated in resporbable carrier nanoparticles of biologic or synthetic origin.

14 . The method of claim 11 , wherein the effective amount of the LXA 4 , resolvin, or analog thereof is an amount that increases plaque stabilization and/or the number of unstable/vulnerable plaques.

15 . The method of claim 11 , further comprising administering at least one additional agent that treats the arterial disease.

16 . The method of claim 15 , wherein the additional agent is selected from the group consisting of anti-inflammatory agents.

17 . The method of claim 11 , wherein the LXA 4 analog is 9,12 benzo-LXA 4 .

18 . The method of claim 11 , wherein the resolvin is Resolvin E1.

19 . The method of claim 11 , wherein the administration is topical.

20 . The method of claim 11 , further comprising the step of administering a therapeutically effective amount of LXA 4 or an analog thereof to the at least one arterial lesion at least one time after surgery completion.

21 . The method of claim 20 , wherein the LXA 4 analog is 9,12 benzo-LXA 4 .

22 . The method of claim 11 , wherein the resolvin is Resolvin E1.

23 . The method of claim 11 , wherein the administration is topical.

24 . The method of claim 20 , further comprising administering at least one additional agent that treats the arterial disease at least one time after surgery completion.

25 . The method of claim 20 , wherein the additional agent is selected from the group consisting of anti-inflammatory agents.